Resilience has bought cell-free protein synthesis tech firm SwiftScale Biologics in a deal designed to support novel therapeutic research. The San Diego based contractor – officially called National Resilience – announced the acquisition late last week, citing growing biopharmaceutical industry interest in cell-free protein synthesis as the prompt for the deal. Resilience CEO Rahul Singhvi suggested the approach could help industry overcome some of the hurdles that complicate commercial manufacture and scale-up. “Biologics production today is limited to what can…

Filtration firm Donaldson Company has acquired Solaris Biotechnology to bolster its presence in the life sciences space. Meanwhile, Ecolab has completed the $3.7 billion acquisition of purification firm Purolite. Minneapolis-based filtration firm Donaldson will add a range of bioreactors, fermenters, and tangential flow filtration systems through the €41 million ($47 million) addition of Italy’s Solaris. “This acquisition is an important step on our journey towards strengthening our presence in the life sciences market,” said Tod Carpenter, CEO of Donaldson. “With…

Sanofi will add a potential acne vaccine candidate to its pipeline through the acquisition of Origimm Biotechnology. Sanofi is set to acquire Austrian biotechnology firm Origimm, which specializes in the discovery of virulent skin microbiome components and antigens causing skin diseases for an undisclosed fee. The move sees the French pharma giant  add a potential first-in-class vaccine candidate ORI-001 to treat acne vulgaris, a stigmatizing skin condition that affects millions of people of different ages worldwide. ORI-001 is a therapeutic…

BlueJay Therapeutics selects Lonza to manufacture its HBV antibody candidate; BiVictriX contracts Abzena; Samsung Biologics will manufacture drug substance for GreenLight’s mRNA COVID-19 vaccine candidate. Great to have you here for BioProcess Insider’s CDMO round-up. First up in our contract development manufacturing organization (CDMO) round-up is Swiss company Lonza, which BlueJay Therapeutics recently selected to provide a tailored program to support production of BJT-778 a monoclonal antibody (mAb) drug candidate targeting chronic hepatitis B virus (HBV) infection. Under terms of…

Pfizer’s chief financial officer Frank D’Amelio will retire from his position after 15 years at the firm, prompting an external search for his successor. Meanwhile, Joe Biden nominates Robert Califf for US FDA chief. Sit back, relax, and enjoy this week’s Ins &Outs. Pfizer announced D’Amelio’s planned departure from the company and stated he has agreed to stay on board in a consulting role while the firm externally search for a chief financial officer (CFO). Pfizer claim that during D’Amelio’s…

CGT Catapult has partnered with Deep Science Ventures to tackle issues and create companies that address needs in the advanced therapy sector. Together, the Cell and Gene Therapy Catapult (CGT Catapult) and London , UK-based venture creator Deep Science Ventures (DSV) aim to drive innovation and employment opportunities in the advanced therapy industry by addressing challenges in the sector and creating companies to support better patient outcomes. “The CGT Catapult will leverage its world-class technical and regulatory expertise in ATMPs alongside…